Table 1.

Selected published studies of HLA-haploidentical SCT

Authors	N	Median age (years)	T depletion	Graft failure (%)	GVHD (%)			NRM (%)*	Relapse (%)*	Overall survival (%)*	EFS (%)*
					Acute II–IV	Acute III and IV	Chronic
Myeloablative conditioning
Szydlo et al.1	340	25	Ex vivo (49%)
1 Ag MM				9	44	a	52	b	28–65	—	15–36
2 Ag MM				16	56		60		37–45	—	20–25
O’Reilly et al.7	52		Ex vivo	c	9	3				20
Mehta et al.8	201	23	In (71%)+ ex vivo	2	13	—	15		31	18	19
Aversa et al.9	104	33	Ex vivo	9	8	—	7	37	25	39	—
Lu et al.10	135	24	In vivo	1	40	16	55	22	18	d
Nonmyeloablative conditioning
Rizzieri et al.11	49	e	In vivo	14	16	—	14	31	—	31	—
Luznik et al.12	68		In vivo	13	34	6	22	f	51	36	26

Boxes illustrate salient results:

^aeffect of HLA mismatch on severe GVHD after myeloablative, T-cell-replete BMT

^bexcessive NRM in early trials of haploidentical SCT

^cincreased risk of graft failure with ex vivo graft TCD without intensive immunosuppressive conditioning

^dimproved outcome of myeloablative SCT using in vivo TCD

^e,fnonmyeloablative conditioning permits transplantation of older patients with reduced treatment-related mortality. See text for details of the studies.

^*Data on NRM (non-relapse mortality) are for 1–2 years after transplantation. Data on relapse, overall survival and EFS are for 1–2 years (all studies except Lu et al.¹⁰) or for 5 years after transplantation (Lu et al.). 1 Ag MM = 1 HLA Ag mismatch.